Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295282 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis
A Phase 1 study of Ulcerative Colitis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 5
- Study locations
NCT00295282 is a Phase 1 study of Ulcerative Colitis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT00295282, a Phase 1 study of Ulcerative Colitis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase I dose-escalation study of MDX-1100. patients with ulcerative colitis will be enrolled into one of four dose cohorts, to receive of MDX-1100 at 0.3, 1.0, 3.0 or 10mg/kg. Three to six patients will be enrolled at each dose level, starting at the lowest dose level, for a maximum of 24 patients to be enrolled into the study. The study is designed to establish the safety and tolerability of single doses of MDX-1100 administered in dose-escalating cohorts to patients with ulcerative colitis. Other study objectives include characterizing a pharmacokinetic profile and pharmacodynamic effects of MDX-1100 and determination of immunogenic response to MDX-1100.
Conditions Studied
Interventions
- DRUG MDX-1100 (anti-CXCL10 human monoclonal antibody)
Study Locations (5)
California
- Cedars-Sinai Medical Center - Los Angeles
Florida
- DMI Health Care Group, Inc. - Largo
Maryland
- Metropolitan Gastroenterology Group, PC - Chevy Chase
New Jersey
- University of Medicine and Dentistry of New Jersery (UMDNJ) - New Brunswick
New York
- Mount Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00295282
The ClinicalTrials.gov registry entry for NCT00295282 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which MDX-1100 (anti-CXCL10 human monoclonal antibody) is the first listed.
NCT00295282 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT00295282 about?
NCT00295282 is a clinical study titled "A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis". This is a Phase I dose-escalation study of MDX-1100. patients with ulcerative colitis will be enrolled into one of four dose cohorts, to receive of MDX-1100 at 0.3, 1.0, 3.0 or 10mg/kg. Three to six patients will be enrolled at each dose level, starting at the lowest dose level, for a maximum of 24 ...
What is the current status of trial NCT00295282?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2006-01. Estimated completion is 2008-01.
What conditions does trial NCT00295282 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT00295282?
The interventions under investigation include: MDX-1100 (anti-CXCL10 human monoclonal antibody) (DRUG).
Who is sponsoring clinical trial NCT00295282?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00295282 being conducted?
This trial has 5 study locations across California, Florida, Maryland, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
RECRUITING · Phase 1
-
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
CP101 for the Treatment of Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Angiographic Delivery of AD-MSC for Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.